Pharmaceuticals

BENZALKONIUM CHLORIDE

API impurity for use in pharmaceutical applications. It is also known as BZK, BKC, BAC.Benefits:It is a mixture of alkyl benzyl dimethyl ammonium chlorideActs as a biocide (used in sanitizers, antiseptics, mouthwash etc) and a phase transfer agent (synthesis of organic compounds)

BENZOTHIADIAZINE

API impurity has possible use in pharmaceutical drugs.Benefits:It is a bicyclic heterocyclic benzene derivative with the heterocycle containing two nitrogens and one sulfur

BENZYDAMINE IN HOUSE IMPURITY

API impurity has possible use in topical application for pain relief and anti-inflammatory treatment of the mouth, throat, or musculoskeletal system.Benefits:Available in yellow colored liquid form

BETAMETHASONE DIPROPIONATE IMP D

API impurity recommended for use in treating inflammatory skin conditions such as dermatitis, eczema and psoriasis.Benefits:It is a super high potency corticosteroid It is a glucocorticoid steroid with anti-inflammatory and immunosuppressive abilities

BOSENTAN DIMER IMPURITY

API impurity is designed for the treatment of pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.Benefits:It functions as a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals

BUCLIZINE- IN HOUSE IMPURITY (LEVOSETIRIZIN)

API impurity for use in pharmaceutical applications.Benefits:Available in white colored powder form

BUSULFAN STANDARD

API impurity suitable for cancer drug applications. It is a cell cycle non-specific alkylating antineoplastic agent.Benefits:Available in white colored solid form

CABAZITAXEL

API impurity is used in pharmaceutical applications.Benefits:Semi-synthetic derivative of a natural taxoidIt is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapyIt was developed by Sanofi-Aventis and approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010